Liquidia (LQDA) Non-Current Deferred Tax Liability (2026)
Liquidia (LQDA) posted Non-Current Deferred Tax Liability of $914000.0 for Q2 2026, up 4.7% on a QoQ basis from $873000.0 in Q1 2026.
Powered by 
Analysis
Liquidia (LQDA) Non-Current Deferred Tax Liability (2026) Analysis & Trends
Liquidia has reported Non-Current Deferred Tax Liability for 1 years, with the latest figure at $914000.0 in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn |
| 2 | AbbVie | 442.18 Bn | 435.61 Bn | 12.70 Bn |
| 3 | Merck | 366.59 Bn | 359.45 Bn | 12.21 Bn |
| 4 | Novartis Ag | 266.49 Bn | 258.80 Bn | 11.24 Bn |
| 5 | Pfizer | 159.09 Bn | 147.39 Bn | 10.94 Bn |
| 6 | Sanofi | 52.34 Bn | 44.96 Bn | 10.79 Bn |
| 7 | Revolution Medicines | 44.08 Bn | 44.08 Bn | - |
| 8 | Incyte | 25.38 Bn | 20.85 Bn | 1.57 Bn |
| 9 | United Therapeutics | 21.53 Bn | 18.87 Bn | 683.80 Mn |
| 10 | Liquidia | 6.12 Bn | 5.83 Bn | 160.92 Mn |